Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors;Ocena stȩżenia białka p53 oraz rozpuszczalnej formy liganda sFasL jako wskaźników procesu apoptozy w surowicy u chorych z łagodnymi i złośliwymi pierwotnymi nowotworami pȩcherzykowymi tarczycy

Endokrynologia Polska

Volumn 57, Issue 4, 2006, Pages 320-325

  Kołomecki, Krzysztof ^a   MacIaszczyk, Piotr ^a   Stȩpień, Henryk ^b   Cywiński, Jacek ^a   Cielecka, Justyna ^a   Stȩpień, Tomasz ^b   Kuzdak, Krzysztof ^b  

^a Department of General Surgery   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Follicular thyroid cancer; P53; SFasL

Indexed keywords

FAS LIGAND; PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ADENOMA; APOPTOSIS; ARTICLE; BLOOD; CANCER INVASION; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; APOPTOSIS; DIAGNOSIS, DIFFERENTIAL; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049178789     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lange D, Sporny S, Sygut J i wsp. Kryteria różnicowania miêdzy rakiem brodawkowatym a pêcherzykowym tarczycy - pierwsze wnioski z badania wieloośrodkowego. Wiad Lek 2001; 54 (supl. 1): 42-53.
2. Koźlak J, Duś D. Udział receptora Fas i jego liganda FasL w progresji nowotworowej? Nowotwory J of Oncology 2002; 52.
3. Szala S. Swoista indukcja apoptozy w komórkach nowotworowych. Nowotwory 2000; 50 (2): 111-121.
4. Vaux DL, Korsmeyer J. Cell death in development. Cell 1999; 96: 245-254.
5. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
6. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family protenases. J Biol Chem 1999; 274: 20 049-20 052.
7. Podack ER. How to induce involuntary suicide: the need for di-peptidyl peptidase I. Proc Natl Acad Sci USA 1999; 96: 8812-8814.
8. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
9. Daniel PT, Wieder T, Sturm I i wsp. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15: 1022-1032.
10. Midis GP, Shen Y, Owe-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic malignancy. Cancer Res 1 in non-hematopoietic malignancy. Cancer Res 1996; 56: 3870-3874.
11. Tanaka M, Toshimitsu L, Adachi M i wsp. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
12. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 94: 695-698.
13. Bennett M, Macdonald K, Chan SW i wsp. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science1998; 282: 290-293.
14. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 281: 695-698.
15. Rybiński K, Narȩbski J, Pomorski L. Współ czesne leczenie chirurgiczne raka tarczycy. Endokrynol Pol. 1999; 50 (supl. 2 do z. 4): 63-72.
16. O'Connell J, O'Sullivan GC, Collins JK i wsp. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184 (3): 1075-1082.
17. Hahne M, Rimoldi D, Schroter M i wsp. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
18. Strand S, Hofmann WJ, Hug H i wsp. Lympocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
19. Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 1996; 149: 429-437.
20. Hohlbaum AM, Moes S, Rothstein AM. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191: 1209-1220.
21. Konno R, Takano T, Sato S i wsp. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000; 6: 3576-3580.
22. Shudo K, Kinoshita K, Imamura R i wsp. The membrane - bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001; 31: 2504-2511.
23. Hosaka N, Oyaizu N, Kaplan MH i wsp. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. J Infect Dis 1998; 178 (4): 1030-1039.
24. Nakamoto Y, Kaneko S, Buttner SW i wsp. Inhibition of peripheral blood lympocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma. Oncol Rep 1999; 6 (4): 733-739.
25. Taieb J, Mathurin P, Poynard T i wsp. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 1998; 351 (9120): 1930-1931.
26. Shiota G, Oyama K, Noguchi N i wsp. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res Commun Mol Pathol Pharmacol 1998; 101 (1): 3-12
27. Sano H, Asano K, Minatoguchi S i wsp. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Nephron 1998; 80 (2): 153-161.
28. Ichikura T, Majima T, Uchida T i wsp. Plasma soluble ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep 2001; 8: 311-314.
29. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187: 127-137.
30. Mulder JW, Wielenga VJ, Pals ST i wsp. p53 and CD4 as clinical markers of tumours progression in colorectal carcinogenesis. Histochem J 1997; 29 (6): 439-452.
31. Khan S, Do KA, Kuhnert P i wsp. Diagnostic value of p53 im-munohistochemistry in Barrett's esophagus: an endoscopic study. Pathology 1998; 30 (2): 136-140.
32. Harris CC. P53: at the crossroads of molecular carcinogenesis and molecular epidemiology. J Investig Dermatol Symp Proc 1996; 1 (2): 115-118.
33. Gorczyca W, Melamed MR, Darzynkiewicz Z. Programowana śmierć komórek (apoptoza). Pat Pol 1993; 44 (3): 113-119.